Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientlymphomaheartventricularradiation
  Phrases that lowered it: breaststopgrowthupperaminotransferase
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 17.4% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 9.5% (raises risk) · Sponsor's track record
• Sponsor's past trials: 453 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 267 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 93.9% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer NCT00684983 · started 2008 · scored riskier than 58% of active trials completed
• Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer NCT05041101 · started 2021 · scored riskier than 85% of active trials terminated
• Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer NCT00738881 · started 2008 · scored riskier than 39% of active trials terminated
• Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer NCT02860000 · started 2017 · scored riskier than 77% of active trials completed
• TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer NCT01294293 · started 2011 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.